Sermorelin side effects

The effects most commonly described for injectable growth hormone-releasing analogues are local: reactions at the injection site such as redness, swelling, discomfort or itching. These are the reports that dominate the literature for this class.

Systemic effects described across the class include flushing, headache and gastrointestinal upset. Effects on the growth hormone axis itself are the reason monitoring exists, and are the province of the prescriber rather than of a directory.

We are deliberately not publishing a frequency table. Frequencies come from controlled studies of a defined product, and the preparations reaching patients now are not that product.

An approved medicine carries an adverse reactions section maintained under a regulatory obligation, built from controlled trials and updated through post-marketing surveillance. A compounded preparation carries no such thing, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing.

FDA's stated concerns for peptides in this family are instructive about where the uncertainty sits: immunogenicity risk for certain routes of administration, complexity in characterising the peptide and its related impurities, and in several cases limited or no human safety data for the proposed routes. Those are concerns about the preparation as much as about the molecule.

Two vials from different pharmacies are not necessarily the same thing, which is exactly why the pharmacy question keeps recurring on these pages.

Contact the prescriber who supplied it. If you cannot identify or reach a prescriber, that is itself informative about the service you used.

Adverse events associated with compounded products can be reported to FDA through MedWatch. Reporting matters more than usual in this category precisely because there is no trial dataset filling the gap.

Keep the vial and its label. The pharmacy name on it is the thread that makes any subsequent investigation possible.

• What should I expect in the first weeks, and what would you consider a reason to stop?
• How do I reach you if something happens outside office hours?
• Which pharmacy prepares this, and is it a 503A pharmacy or a registered 503B outsourcing facility?
• What are you monitoring, how often, and what result would change the plan?
• How does this interact with everything else I take?

Dosing is determined by a licensed provider, and so is whether to prescribe at all.

• FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — retrieved 2026-08-06
• FDA — FD&C Act Provisions that Apply to Human Drug Compounding — retrieved 2026-08-06
• FDA — Human Drug Compounding Laws — retrieved 2026-08-06